|
otcstockexchange.com: GNTA, ACTC, VRGD, SOPW - OTCStockExchange.com Stock Alert
(M2 PressWIRE Via Acquire Media NewsEdge)
RDATE:06012009
Rochester, NY -- OTCStockExchange.com's "Stock Watch Alert" this
morning are Genta Incorporated (OTCBB: GNTA), Advanced Cell Technology,
Inc. (Pink Sheets: ACTC), Veridigm, Inc. (Pink Sheets: VRGD), Solar
Power, Inc. (OTCBB: SOPW).
Sign-up for our FREE Stock Alerts at http://www.otcstockexchange.com !
Genta Incorporated
(OTCBB: GNTA -
http://finance.aol.com/quotes/genta-incorporated/gnta/nab ) (Mon, Jan
5, 2009) Genta Incorporated announced that the Company has received
notice from the U.S. Food and Drug Administration (FDA) that tesetaxel,
the latest addition to Genta's oncology product portfolio, has been
granted designation as an "Orphan Drug" for treatment of patients with
advanced gastric cancer. Orphan drug status provides for a period of
marketing exclusivity, certain tax benefits, and an exemption from
certain fees upon submission of a New Drug Application. As a late Phase
2 agent, the Company believes tesetaxel is the leading oral taxane
currently in clinical development.
In the completed Phase 2 study, 35 patients with advanced gastric
cancer were treated with tesetaxel at doses ranging from 27 to 35 mg/m2
once every three weeks. All patients had received extensive prior
treatment, having failed a combination regimen that included cisplatin
plus 5-fluorouracil or Xeloda , and all but 2 patients had received a
third chemotherapy drug with this regimen. Final intent-to-treat
analysis, including all patients enrolled in the study, showed that 5
patients achieved a partial response, 2 patients achieved a partial
response unconfirmed by CT scan, and 14 patients achieved stable
disease, for an overall major response rate of 20% and a
disease-control rate of 60%. The most serious adverse reaction was
Grade 3-4 neutropenia, which occurred in 57% of patients. Six patients
failed to complete the first course of treatment. Five patients died on
study from differing causes that included intestinal perforation,
pneumonia, hepatic failure, hemorrhagic shock, and rapid disease
progression. One patient withdrew before receiving the first treatment
dose.
"These response data for tesetaxel in a critically ill patient
population show clinical activity at levels that are at least
comparable to studies with other taxanes," said Dr. Raymond P. Warrell,
Jr., Genta's Chief Executive Officer. "Based on these data, we have
consulted extensively with international experts and will be defining a
global registration path for tesetaxel as a 2nd-line treatment for
patients with advanced gastric cancer. FDA designation as an Orphan
Drug provides important assistance in the clinical development process."
Advanced Cell Technology, Inc.
(Pink Sheets: ACTC -
http://finance.aol.com/quotes/advanced-cell-technology-inc/actc/nao )
(Mon, Jan 5, 2009) Advanced Cell Technology, Inc. ("ACT") reported that
it is feasible to differentiate human embryonic stem cells (hESCs) into
functional human vasculature. The research, which appears in the
January issue of the journal Regenerative Medicine, shows for the first
time that human progenitor cells -known as hemangioblasts- have the
potential for both endothelial cell (EC) and vascular smooth muscle
cell (SMC) lineage differentiation. This dual potentiality is critical
for the effective treatment of human vascular disease, especially the
repair and formation of mature and larger-size (non-capillary) vessels.
"The cells participated in the formation of new blood vessels -both
capillaries and larger vessels-and were capable of repairing damaged
vessels in multiple vasculatures," said Robert Lanza, M.D., Chief
Scientific Officer at ACT, and senior author of the study. "The cells
restored blood flow in ischemic limbs to near normal levels. They also
showed a similar regenerative capacity after myocardial infarction and
participated in the repair of vascular injury in diabetic animals. The
formation of mature and functional vasculature, except for capillary
vessels, requires the interaction of endothelial and smooth muscle
cells, the later playing a critical role in the structural and
functional support of the vascular network. Thus, the ability to
generate large numbers of these progenitor cells makes them an ideal
source of cells for the treatment of human diseases caused by deficient
vessel growth."
Although endothelial cells play an essential role in vasculogenesis and
angiogenesis and form capillary vasculatures, they alone cannot
complete the process of vessel growth and development. Vascular smooth
muscle cells play a critical role in the support of the vascular
network by stabilizing nascent endothelial vessels during vascular
development and blood vessel growth. This outer layer of cells also
protects the fragile channels from rupture and helps control blood flow.
Until now there was no evidence that blast cells (hemangioblasts) or
their equivalents generated from hESCs possessed the ability to
differentiate into smooth muscle cells. "The hESC-derived smooth muscle
expressed SMC-specific markers (á-SM actin and calponin) and contracted
upon stimulation with carbachol," stated Shi-Jiang Lu, first author of
the paper. "When implanted in nude mice, the cells formed
microvasculature with endothelial cells in Matrigel. The cells
differentiated into both ECs and SMCs, and incorporated into blood
vessels after injection into ischemic tissues, indicating that these
cells are functional both in vitro and in vivo."
"We believe these cells could play an important future therapeutic role
for patients with vascular disease," stated William M. Caldwell, CEO
and Chairman of ACTC. "We are pleased to continue this work through our
new joint venture with CHA Biotech Co, Ltd. (CHA). ACT scientists will
work with the new company "Stem Cell & Regenerative Medicine
International" to help translate this research into clinical therapies."
The paper's other researchers are Yordanka Ivanova, Qiang Feng, and
Chenmei Luo.
Veridigm, Inc.
(Pink Sheets: VRGD -
http://finance.aol.com/quotes/veridigm-inc/vrgd/nao ) (Mon, Jan 5,
2009) Veridigm, Inc. announced the Board has initiated final
preparations for Mobile Media Unlimited, Inc. to be traded as a public
company. Veridigm, Inc. (DE) will be name changed to Mobile Media
Unlimited Holdings, Inc. (DE) in due course.
The Veridigm Board of Directors and MMU Advisors welcomes incoming
Chairman, Chief Executive Officer Anthony Sasso effective Jan 01 2009.
Veridigm President Gary Freeman stated: "We have gone to extraordinary
lengths to ensure that the Veridigm entity is up to date in all areas
of previously unpaid taxation and that Veridigm is in good standing.
This arduous task was necessary for the caliber of MMU clients who
require qualifying 'means tests,' as well as long overdue Veridigm
housekeeping in preparation for Y/E 2008 consolidated auditing and re
filing for OTC BB listing status. Simultaneously, MMU's investors
garnered control of a 'to be named' secondary US public company which
will be utilized for alternative MMU financed projects, proprietary
database research and analysis tools, licensing & branding of
applications to 3rd parties, joint ventures & other miscellaneous
investments that do not immediately qualify as MMU/Veridigm core
competencies."
Manny J. Shulman, managing partner of Shulman and Associates LLC who
advises Mr. Sasso, MMU & Veridigm, commented: "We are now satisfied
that the criteria and qualifications of Veridigm are habitable for the
MMU deal. Veridigm has just effected common stock cancellations to its
treasury of 40,111,000 or 14.6% shares of common stock. We have
formally closed Veridigm's Regulation D 504 offering as of 12/31/08 and
irrevocably cancelled all outstanding Reg D 504 exemption legal
opinions, Blue Sky exemptions and previously issued 504 shares are no
longer exempt from registration. The Company is reporting a not
inconsequential & wholly unexplainable differential between its free
trading common share count issued and outstanding as reported by CEDE &
Co/DTCC and its common share NOBO/OBO count as reported by S&P as
compared to its recent Transfer Agent ledger. We do not foresee an
immediate resolution of this suspicious differential and we believe
this differential may be responsible for VRGD's recent and extended
price and volume volatility."
Mr. Shulman continued: "The Company's equity capital remains
510,000,000 shares authorized. 72% of 100% of the controlling VRGD
super voting preferred shares are owned by MMU entities & Mr. Sasso.
These preferred shares have no conversion ability to common under
present restrictions. The remaining 8% of VRGD preferred shares are now
owned by two institutional clients who have no ability to convert to
common under present restrictions. For more information about MMU's
unique business platform please visit www.mmusms.com."
Solar Power, Inc.
(OTCBB: SOPW - http://finance.aol.com/quotes/solar-power-inc/sopw/nab )
(Mon, Jan 5, 2009) Solar Power, Inc. ("SPI") has entered into a
one-year supply agreement with JA Solar Holding Co., Ltd. ("JA Solar")
(NASDAQ: JASO). JA Solar has committed to supply up to 60 megawatts of
its 6" polycrystalline photovoltaic ("PV") cells based on monthly
requirements from SPI. Based in Hebei, China, JA Solar is one of the
world's top producers of high-performance solar cells. The cells will
be used for the ongoing production of SPI's solar modules and to meet
growing demand for the company's products in Europe, Asia, and for
turnkey systems in the United States. Supply to SPI begins immediately.
"We are excited about our agreement with JA Solar. Their products are
known for quality and performance and we are very fortunate to be able
to integrate them into our own," said Steve Kircher, CEO Solar Power,
Inc. "This is a true strategic relationship with strong mutual benefit.
It will allow us to leverage our vertical integration business model
through a significant amount of supply and we will be able to offer
competitive pricing that we believe is unprecedented," Mr. Kircher
added. "It also provides our SPI commercial operations and our growing
Yes! Solar SolutionsTM franchise network with strong advantages in cost
of installation and will have a significant positive effect on our
competitive position relative to international sales," Mr. Kircher
concluded.
The agreement provides SPI with immediate supply of high-quality cells
to meet anticipated production requirements of the company's family of
solar modules during 2009. "We are happy to be providing Solar Power,
Inc. with cells for their high-quality PV modules," said Mr. Samuel
Yang, CEO of JA Solar Holding Co., Ltd. "This agreement represents a
strategic alliance between our company and one of the leading solar
solution providers in the world today. Through SPI we will be able to
expand sales of our cells and gain deeper penetration into the U.S.
market."
About OTCStockExchange.com
OTCStockExchange.com (OTCS) is a leading investor relations firm whose
primary focus is promoting awareness among brokers, investors, and
others in the investment community who are interested in small and
micro-cap companies. OTCS is dedicated to helping publicly traded
companies gain the exposure they need to move forward with the
development of their business plans. OTCS's goal is to feature equity
investments in micro or small capitalization companies that have the
potential for long-term appreciation. OTCS provides all investors with
the latest news, press releases, investment opinions, and research
reports for all the companies highlighted on the site. OTCS offers a
free financial newsletter. To subscribe or get more information, visit
our home page located at http://www.otcstockexchange.com .
We offer many investor relations programs to public companies. To
feature a company on our web site or in our daily Newsletter or Mid-Day
Stock Alert, please contact Chris Wheeler at 585-330-8514 , or via
email at info@otcstockexchange.com .
OTCS's affiliates, officers, directors and employees may also have
bought or may buy the shares discussed in this opinion and may profit
in the event of a rise in value. OTCS will not advise as to when it
decides to sell and does not and will not offer any opinion as to when
others should sell; each investor must make that decision based on his
or her judgment of the market.
OTCStockExchange.com (OTCS) based upon information believed to be
reliable herein prepared all material. The information contained herein
is not guaranteed by OTCS to be accurate, and should not be considered
to be all-inclusive. The companies that are discussed in this opinion
have not approved the statements made in this opinion. This opinion
contains forward-looking statements that involve risks and
uncertainties. This material is for informational purposes only and
should not be construed as an offer or solicitation of an offer to buy
or sell securities. OTCS is not a licensed broker, broker dealer,
market maker, investment banker, investment advisor, analyst or
underwriter. Please consult a broker before purchasing or selling any
securities viewed on http://www.otcstockexchange.com or mentioned
herein. OTCS has been compensated by third party shareholders or with
cash from the company on behalf of one or more of the companies
mentioned in this opinion.
This release contains "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section
21E the Securities Exchange Act of 1934, as amended and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans,
results, or strategies and are generally preceded by words such as
"may", "future", "plan" or "planned", "will" or "should", "expected,"
"anticipates", "draft", "eventually" or "projected". You are cautioned
that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results
to differ materially from those projected in the forward-looking
statements, including the risks that actual results may differ
materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a companies'
annual report on Form 10-K or 10-KSB and other filings made by such
company with the Securities and Exchange Commission. You should
consider these factors in evaluating the forward-looking statements
included herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date
hereof and OTCS undertakes no obligation to update such statements.
CONTACT: Chris Wheeler, OTCStockExchange.com
Tel: +1 585 330 8514
e-mail: info@otcstockexchange.com
WWW: http://www.otcstockexchange.com
((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).
Copyright ? 2009 M2 Communications Ltd.
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, January 20-22, 2010. Miami, FL.
